254 related articles for article (PubMed ID: 6357025)
41. Serratia marcescens bacteremia at a medical center in southern Taiwan: high prevalence of cefotaxime resistance.
Shih HI; Lee HC; Lee NY; Chang CM; Wu CJ; Wang LR; Ko NY; Ko WC
J Microbiol Immunol Infect; 2005 Oct; 38(5):350-7. PubMed ID: 16211144
[TBL] [Abstract][Full Text] [Related]
42. SME-3, a novel member of the Serratia marcescens SME family of carbapenem-hydrolyzing beta-lactamases.
Queenan AM; Shang W; Schreckenberger P; Lolans K; Bush K; Quinn J
Antimicrob Agents Chemother; 2006 Oct; 50(10):3485-7. PubMed ID: 17005839
[TBL] [Abstract][Full Text] [Related]
43. Five cases of high-level aminoglycoside resistant enterococcal septicaemia in Singapore.
Chiew YF
Singapore Med J; 1994 Apr; 35(2):177-9. PubMed ID: 7939816
[TBL] [Abstract][Full Text] [Related]
44. Synergic post-antibiotic effect of amikacin in combination with beta-lactam antibiotics on gram-negative bacteria.
Isaksson B; Hanberger H; Maller R; Nilsson LE; Nilsson M
J Antimicrob Chemother; 1991 Jul; 28(1):25-34. PubMed ID: 1769941
[TBL] [Abstract][Full Text] [Related]
45. Investigation of the presence of different broad-spectrum beta-lactamases among clinical isolates of Enterobacteriacae.
Nagy E; Pragai Z; Kóczián Z; Hajdú E; Fodor E
Acta Microbiol Immunol Hung; 1998; 45(3-4):433-46. PubMed ID: 9873949
[TBL] [Abstract][Full Text] [Related]
46. [Nosocomial infections caused by multi-resistant Serratia marcescens at a university clinic--clinical aspects and drug resistance].
Halle E; Grauel EL; Klare I; Bollmann R; Buchholz P; Scholowska-Köhler W; Witte W; Göldner B; Baumann B
Padiatr Grenzgeb; 1989; 28(5):299-309. PubMed ID: 2695885
[TBL] [Abstract][Full Text] [Related]
47. Plasmid-independent resistance of 'gray' colony variants of a strain of Serratia marcescens resistant to amikacin, cefotaxime and lamoxactam.
Traub WH; Spohr M; Bauer D
Chemotherapy; 1983; 29(4):265-74. PubMed ID: 6307604
[TBL] [Abstract][Full Text] [Related]
48. [Genes of resistance to aminoglycoside antibiotics in clinical strains of Serratia marcescens and the enzyme encoded by them].
Kolganov AN; Vakulenko SB
Antibiot Khimioter; 1992 Nov; 37(11):10-4. PubMed ID: 1300924
[TBL] [Abstract][Full Text] [Related]
49. Reevaluation of Enterobacteriaceae MIC/disk diffusion zone diameter regression scattergrams for 9 beta-lactams: adjustments of breakpoints for strains producing extended spectrum beta-lactamases.
Jones RN; Craig WA; Ambrose PG; Dudley MN; Pottumarthy S
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):235-46. PubMed ID: 16105568
[TBL] [Abstract][Full Text] [Related]
50. Loss of an aminoglycoside resistance plasmid by Serratia marcescens during treatment of meningitis with amikacin.
Rubens CE; McGee ZA; Farrar WE
J Infect Dis; 1980 Mar; 141(3):346-50. PubMed ID: 6988523
[TBL] [Abstract][Full Text] [Related]
51. Infection with netilmicin resistant Serratia marcescens in a special care baby unit.
Lewis DA; Hawkey PM; WattsJA ; Speller DC; Primavesi RJ; Fleming PJ; Pitt TL
Br Med J (Clin Res Ed); 1983 Dec; 287(6406):1701-5. PubMed ID: 6315130
[TBL] [Abstract][Full Text] [Related]
52. In vitro activities of beta-lactam and aminoglycoside antibiotics. A comparative study of 20 parenterally administered drugs.
Fass RJ
Arch Intern Med; 1980 Jun; 140(6):763-8. PubMed ID: 7387270
[TBL] [Abstract][Full Text] [Related]
53. [Estimation of level of aminoglycosides susceptibility of bacterial strains isolated from patients with systemic and general infections].
Kowalska-Krochmal B; Dolna I; Dobosz A; Wrzyszcz E; Gościniak G
Med Dosw Mikrobiol; 2008; 60(3):205-14. PubMed ID: 19143174
[TBL] [Abstract][Full Text] [Related]
54. [Statistical observation of urinary tract infections by Serratia marcescens].
Kamiryo Y; Sakatoku J
Hinyokika Kiyo; 1983 Apr; 29(4):401-10. PubMed ID: 6203384
[TBL] [Abstract][Full Text] [Related]
55. Amikacin treatment of Serratia septicemia in critically ill patients.
Mosquera JM; de Villota ED; de la Serna JL; Diez-Balda V; Tomás MI; Galdos P; Rubio JJ
Crit Care Med; 1981 Sep; 9(9):633-6. PubMed ID: 7023839
[TBL] [Abstract][Full Text] [Related]
56. Aminoglycoside resistance patterns of Serratia marcescens strains of clinical origin.
Coria-Jiménez R; Ortiz-Torres C
Epidemiol Infect; 1994 Feb; 112(1):125-31. PubMed ID: 8119351
[TBL] [Abstract][Full Text] [Related]
57. Emergence of resistance to beta-lactams, aminoglycosides, and quinolones during combination therapy for infection due to Serratia marcescens.
Sanders CC; Watanakunakorn C
J Infect Dis; 1986 Mar; 153(3):617-9. PubMed ID: 3512733
[No Abstract] [Full Text] [Related]
58. Serratia marcescens bacteremia.
Wong WW; Wang LS; Cheng DL; Lin SJ; Chin TD; Hinthorn DR; O'Connor MC; Huang WK
J Formos Med Assoc; 1991 Jan; 90(1):88-93. PubMed ID: 1679115
[TBL] [Abstract][Full Text] [Related]
59. Antimicrobial susceptibility of clinical isolates of Serratia marcescens.
Alvarez JS; Regueiro B; Garrido MJ
Antimicrob Agents Chemother; 1979 Oct; 16(4):523-4. PubMed ID: 391150
[TBL] [Abstract][Full Text] [Related]
60. [Infection with Serratia marcescens in newborn infants. Clinical aspects, therapy and disease course].
Scharf JW; Wild F; Guggenbichler JP
Monatsschr Kinderheilkd; 1991 Oct; 139(10):695-8. PubMed ID: 1961210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
